Common adverse reactions may include nausea and elevated liver enzymes. Serious adverse reactions may include liver problems and low platelets. Transient elevated levels of cardiac troponin‑I were observed in clinical trials; the clinical importance of these findings is not known. However, cardiac toxicity was seen in studies of other animals. As the medication may reduce the platelet count, platelets may need to be checked before the medication is started, then weekly for the first month and every two weeks for the next two months until the level is back to baseline. Liver function should be monitored for three months after administration.
Onasemnogene abeparvovec
Voretigene neparvovec
Alipogene tiparvovec
Valoctocogene roxaparvovec
Ofranergene obadenovec
Enadenotucirev
Vibegron
Belantamab mafodotin